# Coronary Artery Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/coronary-artery-disease

> 4 upcoming FDA catalysts in coronary Artery Disease: YMI024 (NVS) on Aug to Nov 2027 (topline data readout); YMI024 (NVS) on August 2027 (primary completion); humacyte coronary tissue engineered vessel (ctev, HUMA) on September 2030 (primary completion); humacyte coronary tissue engineered vessel (ctev, HUMA) on Sep to Dec 2030 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2026 to Jan 2027 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Coronary Artery Disease | scheduled | "NCT05360446 (Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05360446)) |
| October 2026 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Coronary Artery Disease | delayed | "NCT05360446 (Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05360446)) |
| Aug to Nov 2027 | [YMI024 topline data readout](https://sec-api.dev/pdufa/ymi024) | NVS | Coronary Artery Disease | scheduled | "NCT07830719 (Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-15 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830719)) |
| August 2027 | [YMI024 primary completion](https://sec-api.dev/pdufa/ymi024) | NVS | Coronary Artery Disease | scheduled | "NCT07830719 (Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-15 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830719)) |
| September 2030 | [Humacyte coronary tissue engineered vessel (ctev) primary completion](https://sec-api.dev/pdufa/humacyte-coronary-tissue-engineered-vessel-ctev) | HUMA | Coronary Artery Disease | scheduled | "NCT07730528 (Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Humacyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07730528)) |
| Sep to Dec 2030 | [Humacyte coronary tissue engineered vessel (ctev) topline data readout](https://sec-api.dev/pdufa/humacyte-coronary-tissue-engineered-vessel-ctev) | HUMA | Coronary Artery Disease | scheduled | "NCT07730528 (Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Humacyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07730528)) |

## Drugs

- [Leqvio (inclisiran sodium)](https://sec-api.dev/pdufa/inclisiran) (NVS)
- [YMI024](https://sec-api.dev/pdufa/ymi024) (NVS)
- [Humacyte coronary tissue engineered vessel (ctev)](https://sec-api.dev/pdufa/humacyte-coronary-tissue-engineered-vessel-ctev) (HUMA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/coronary-artery-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Coronary Artery Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/coronary-artery-disease

```bibtex
@misc{secapidev_indications_coronary_artery_disease_20261116,
  title        = {Coronary Artery Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/coronary-artery-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_coronary_artery_disease_20261116","title":"Coronary Artery Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/coronary-artery-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
